December 5, 2016
Apogenix Reports Final Phase I MDS Data at this Year's American Society of Hematology (ASH) Meeting 

November 4, 2016
Apogenix Reports Significant Progress in Collaboration with CANbridge

November 3, 2016
Apogenix Announces Oral Presentation on APG101 at Upcoming 58th American Society of Hematology (ASH) Meeting & Exposition

July 19, 2016
Apogenix Granted European Patent for the Use of APG101 in the Treatment of Myelodysplastic Syndromes

June 15, 2016
Apogenix Reports Topline Results from Phase I Trial in Myelodysplastic Syndromes with APG101

May 4, 2016
Apogenix to Present at Two Upcoming International Conferences

March 24, 2016
Preclinical Efficacy Data of Apogenix' APG101 in Myelodysplastic Syndromes (MDS) published in Oncotarget

February 16, 2016
Apogenix Receives €3 Million Grant for the Development of a Companion Diagnostic Test for Lead Immuno-Oncology Candidate APG101

January 14, 2016
Apogenix Strengthens U.S. Patent Position for Lead Immuno-Oncology Candidate APG101

January 7, 2016
Apogenix Receives First Milestone Payment from CANbridge Licensing Agreement and Signs Amendment to Include Taiwan


December 15, 2015
Apogenix to Present at J.P. Morgan Healthcare Conference

October 13, 2015
Apogenix to Present at Three Upcoming International Conferences

July 28, 2015
Apogenix Enters into Cooperation with R-Biopharm to Develop Companion Diagnostic Tests for Immuno-Oncology Candidate APG101

July 15, 2015
Apogenix Enters into Licensing Agreement with CANbridge Life Sciences for Immuno-Oncology Candidate APG101 in China 

June 3, 2015
Apogenix appoints Peter Willinger as new CFO

June 1, 2015
Apogenix to present at Jefferies 2015 Global Healthcare Conference


October 28, 2014
Apogenix – Positive Results from APG101 Phase II Clinical Trial Published in Clinical Cancer Research

January 13, 2014
Apogenix' APG101 Demonstrates Significant Prolongation of Overall Survival in Biomarker-Positive Patients in Phase II Trial for the Treatment of Recurrent Glioblastoma

January 7, 2014
Apogenix to Present Phase II Results with APG101 for the Treatment of Recurrent Glioblastoma at Biotech Showcase in San Francisco


December 5, 2013
Apogenix' APG350 Effectively Induces Apoptosis of Tumor Cells via TRAIL Pathway Independent of Fcγ Cross-Linking

July 2, 2013
Apogenix Strengthens Patent Position for Apocept™ (APG101) in Europe and Canada

February 7, 2013
Apogenix Receives FDA Orphan Drug Designation for Apocept™ to Treat Myelodysplastic Syndromes and Initiates Clinical Phase I Study


November 6, 2012
Apogenix’s Apocept™ for Glioblastoma Multiforme Named One of “Top 10 Projects to Watch”

July 26, 2012
Apogenix: APG101 Exceeds Expectations with Controlled Phase II Clinical Trial in Treatment of Recurrent Glioblastoma

May 29, 2012
Apogenix to Present Positive Phase II Results of APG101 in Glioblastoma Multiforme at ASCO

March 8, 2012
Apogenix Announces that APG101 Meets Primary Endpoint in a
Controlled Phase II Trial with Glioblastoma Patients

January 5, 2012
Apogenix Raises € 7.5 Million to Further Advance APG101 to Treat Glioblastoma and other Tumors

January 3, 2012
Apogenix Receives Additional € 2.3 Million BMBF Grant as Partner of the Biotech Cluster Rhine-Neckar


September  20, 2011
Apogenix Successfully Completes Patient Recruitment for Glioblastoma Phase II Trial with APG101

January 24, 2011
Apogenix provides update in the ongoing Phase II clinical trial of APG101 to treat Glioblastoma


May 27,  2010
Data Published in “Nature” Confirms Development of APG101 to Treat Cancer

January 11, 2010
Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in Glioblastoma


November  16, 2009
Apogenix Receives Orphan Drug Designation for APG101 in the US and Positive Opinion on Orphan Product Designation in Europe

October 27, 2009
Apogenix Significantly Strengthens IP Protection for its Clinical Lead Compound APG101

July 29, 2009
Apogenix Receives Research Grants of EUR 2.6 Million as Partner of the Biotechnology Cluster Rhine-Neckar

May 13, 2009
Apogenix Reports Positive Phase I Results on its Lead Compound AGP101


October 7, 2008
Apogenix Starts Phase I With its Lead Compound AGP101

September 19, 2008
Two Grants Totaling EUR 1.65 million by the German Federal Ministry of Education and Research (BMBF) to Support Apogenix ́ Research

April 30, 2008
Apogenix Raises EUR 27.5m in Series B Financing Round

March, 10, 2008
Publication in Cancer Cell Supports Therapeutic Potential of APG101 in Glioblastoma – New indication for lead compound of Apogenix


October 10, 2007
New Publication Underlines Huge Potential of Apogenix ́ Compounds to Efficiently Eliminate Human Cancer Stem Cells

March 12, 2007
BMBF Grants 1.5m Euro to Further Evaluate the Therapeutic Potential of Apogenix' Lead Product APG101


September 15, 2006
Apogenix receives positive opinion on orphan medicinal product designation from the European Medicines Agency for APG101, for prevention of Graft-versus-Host Disease